Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Intranasal Scopolamine (DPI-386)
NCT03874130Phase 1Unknown
- Sponsor
- Defender Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- May 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of scopolamine in major depressive disorder (MDD) (7 arms), sponsored by Defender Pharmaceuticals. Primary endpoint: Safety of Scopolamine HBr at 2 weeks. Status: unknown.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03874130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874130.